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Cancer/Testis Antigens (CTAs) are a promising class of tumor antigens that have a limited expression in somatic tissues (testis,
ovary, fetal, and placental cells). Aberrant expression of CTAs in cancer cells may lead to abnormal chromosome segregation
and aneuploidy. CTAs are regulated by epigenetic mechanisms (DNA methylation and acetylation of histones) and are attractive
targets for immunotherapy in cancer because the gonads are immune privileged organs and anti-CTA immune response can be
tumor-specific. Multiple myeloma (MM) is an incurable hematological malignancy, and several CTAs have been detected in many
MM cell lines and patients. Among CTAs expressed in MM we must highlight the MAGE-C1/CT7 located on the X chromosome
and expressed specificity in the malignant plasma cells. MAGE-C1/CT7 seems to be related to disease progression and functional
studies suggests that this CTA might play a role in cell cycle and mainly in survival of malignant plasma cells, protecting myeloma
cells against spontaneous as well as drug-induced apoptosis.
1. Cancer/Testis Antigens
Tumors generally are immunogenic. They produce proteins
that normally are not expressed in tissues from adults and
therefore are not considered self by the immune system [1].
The idea that immune system can recognize and respond
to these tumor proteins (antigens) was postulated at the
end of the 19th century, when William Coley, a surgeon
at Memorial Sloan-Kettering Cancer Center in New York
(USA), observed that rare events of spontaneous tumor
progression were often preceded by infectious episodes [2].
Tumor immunology began several decades ago, when it
was shown that mice could be immunized against syngeneic
tumors and that the antibodies produced led to specific
rejection of transplanted tumor tissue [3, 4]. Thomas and
Burnet introduced the concept of cancer immune surveil-
lance to describe a mechanism of protection against tumors
in immunocompetent hosts. From this, the development of
tumor vaccines for the human population became a new
possibility for cancer treatment [2].
Tumor-associated antigens were originally discovered in
patients with malignant melanoma. These antigens were
subsequently identified in several types of human tumors.
In normal tissue, they were first described in testicular germ
line. Therefore, genes that express these proteins were called
cancer/testis antigens (CTAs) [5–7].
Thus, the CTAs are a promising class of tumor antigens
due to its limited expression in somatic tissues (germ cells
of the testis, ovary, fetal, and placental cells (trophoblast))
[8–10]. Some CTAs can be expressed in other normal tissues
such as pancreas, liver, and spleen, but the level of expression
is much smaller than observed in germ cells [9].
The study by van der Bruggen et al. [11] was the
first to demonstrate that CTAs could be specific recognized
in vitro by cytotoxic T lymphocytes (CTLs) in patients
with melanoma. It was also possible to obtain autologous
antitumor CTL by cultures of irradiated tumor cells with
blood lymphocytes of melanoma-bearing patient [12, 13].
Testicular and placental cells did not express MHC
(Major Histocompatibility Complex) class I, and the CTAs are
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not recognized by CD8+ cytotoxic T lymphocytes. For this
reason, CTAs are considered excellent targets for antitumor
cell vaccines [14].
The development of vaccines for specific-tumor antigens
depends in part on the identification of a broad spectrum of
immunogenic proteins expressed predominantly in human
cancer. The technique of cloning T-cell epitopes, developed
and published in 1991, led to the discovery of the human
CTAsMAGEA1, BAGE, and GAGE. It was demonstrated that
the products of the mRNAs transcribed and translated these
CTAs almost exclusively in normal testis and various tumor
types [15].
In 1995, the SEREX (Serological Analysis of cDNA Expres-
sion Libraries) technique was used in the search of new tumor
antigens recognized by IgG of cancer patients [16]. Among
the genes identified by SEREX in human tumors were SSX2,
NY-ESO-1, and SYCP-1, which were also, predominantly,
expressed in normal testis and cancer [15].
Scanlan et al. [15] classify the CTAs into four categories,
according to the expression profile measured qualitatively
by conventional RT-PCR (Reverse Transcriptase-Polymerase
Chain Reaction): (1) CTAs exclusively expressed in testis
and tumors (Testis-Restricted), (2) CTAs expressed in two or
more nongametogenic tissues (Tissue-Restricted), (3) CTAs
expressed in 3–6 nongametogenic tissues (Diﬀerentially
Expressed), and (4) CTAs expressed in >6 nongametogenic
tissues (Ubiquitously Expressed) [15, 17, 18].
With the description of an increasing number of CTAs, it
was necessary to implement a nomenclature to diﬀerentiate
these genes. In general, due to lack of information about the
CTA functions in cellular environment, the nomenclature
was based on the chronological order of discovery (e.g.,
MAGEA is CT1; BAGE is CT2). There are cases of multiple
members in CTA families; in those cases, each member of a
family is assigned as a number, for example, SSX1 is CT5.1,
SSX2 is CT5.2, SSX3 is CT5.3, and so on [15].
In 2008, a new classification of CTAs was developed from
in silico analysis of cDNA Database (http://evocontology
.org), MPSS (Massively Parallel Signature Sequencing), CAGE
(Cap Analysis Gene-Expression) and data expression obtained
by conventional RT-PCR. In this classification, the CTAs were
divided basically into three distinct groups: Testis-Restricted
(CTAs expressed in normal adult testis and placenta),
Testis/Brain-Restricted (CTAs expressed in normal adult testis
and in all brain tissues), and Testis-Selective (CTAs were
classified according to the ratio between the expression of
normal adult testis/placenta in relation to others expressed
in normal adult tissues) [6].
More than 250 CTAs were described in the CT antigen
database (http://www.cta.lncc.br). The CTAs can be divided
between those who are located on the X chromosome and
those which are present in other chromosomes (the auto-
somes) [19, 20]. CTAs located on the X chromosome, such as
MAGE-C1/CT7 gene, tend to form families that are normally
expressed in spermatogonia in a coordinated manner [21,
22] (Figure 1). The careful annotation of the genes present
on the X chromosome showed that approximately 10% of
CTAs Testis-Restricted
CTAs Testis/Brain-Restricted
CTAs Testis-Selective
CTAs not found
Figure 1: Distribution of cancer/testis antigens (CTAs) on the X
chromosome. Black regions on chromosome demonstrate a high
density of ESTs (Expressed Sequence Tags). Red Arrow indicates
CTA MAGE-C1/CT7 (Testis-Restricted) (Font: Hofmann et al. [6];
modified by de Carvalho et al. 2011).
them are CTAs and are often coexpressed in tumor cells
[19, 22, 23].
In the testis, CTAs are typically expressed in spermato-
cytes and act in meiosis. Thus, the aberrant expression of
CTAs in cancer cells may lead to abnormal chromosome
segregation and aneuploidy, justifying its importance in
tumorigenesis [22, 24].
CTAs expression is regulated by epigenetic mechanisms
such as hypermethylation of the promoter region of the
genes (DNA methylation) and acetylation of histones [9,
19, 20, 22]. Therefore, since CTAs are not expressed or
have low expression in diﬀerentiated somatic tissues, some
authors suggest that the expression of CTAs in tumor tissue
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may be restricted to cells that retain stem cell properties
[9, 25]. In tumors, a restricted population with stem cell
properties (cancer stem cells) can favor tumor maintenance,
proliferation, and metastasis [9].
The MAGE genes may be involved in tumor transfor-
mation or in some aspects of tumor progression such as
in tumor metastasis [11]. The MAGE genes are frequently
expressed in human tumors of diﬀerent histological types but
not expressed in normal tissues except in male germ cells.
The CTAs encoded by MAGE genes are recognized by CTL
and are strictly tumor-specific [13].
Thus, all CTAs are in principle attractive targets for
immunotherapy in cancer because the gonads are immune
privileged organs and anti-CTA immune response can be
tumor-specific. Vaccines using peptides derived from NY-
ESO-1 (CTAG-1B) have shown clinical benefits in patients
with melanoma [26, 27].
2. CTAs Expression in Multiple Myeloma
Multiple myeloma (MM) is a hematological malignancy
secondary to clonal expansion of plasma cells, characterized
by the presence of monoclonal immunoglobulin in blood
and/or urine, lytic bone lesions, and infiltration of mono-
clonal plasma cells in bone marrow [28–30].
MM corresponds to 1% of all malignancies and 10–
15% of hematologic malignancies and it is the second most
common type of blood cancer [14, 31–34]. In the United
States, 20,000 new cases of MM are diagnosed every year,
with about 11,000 deaths by this disease in the same period
of time [33, 35].
The diagnosis of MM is based on the presence of mon-
oclonal protein (M protein) in serum and/or urine, bone
marrow infiltration by at least 10% of clonal plasma cells,
and damage to one or more target organs (CRAB: hyper-
calcemia, renal failure, anemia, bone lesions). Individuals
with multiple myeloma must be distinguished from those
with Monoclonal Gammopathy of Undetermined Significance
(MGUS) (<10% plasma cells in bone marrow, low levels of
M-protein (<3 g/dL), and no osteolytic lesion), amyloidosis,
or other lymphoproliferative disorders with paraproteinemia
[36].
The characterization of the mechanisms responsible for
the expansion of MM tumor cells is diﬃcult and involves a
series of genetic alterations and changes in the bone marrow
microenvironment, promoting tumor growth and the failure
of the immune system to recognize it [28, 36].
Regardless of prognostic factors, MM remains incurable
with median overall survival of 3–5 years [32, 35, 37–40].
Although it is possible to obtain complete remission of
disease in approximately 25–50% of patients with initial
diagnosis (treated with high-dose melphalan and autologous
hematopoietic stem cell transplant), almost all will relapse
within 2-3 years [18], suggesting that an eﬀective mainte-
nance therapy is needed to control or slow the progression
of the disease [37, 41].
Evidences suggest that small fractions of MM cells escape
the action of chemotherapy and remains undetectable by
conventional methods, explaining the recurrence of the dis-
ease. These small fractions of myeloma cells are considered
potential targets for immunotherapy, either active or passive,
due to two main factors: (1) small fractions of MM cells
can be destroyed by cytotoxic T lymphocytes, and (2) in
allogeneic hematopoietic stem cell transplants, infusion of
donor T cells can eﬃciently eliminate the small fraction of
residual MM cells [18].
The vaccines formulated with antigens associated with
MM can instruct the immune system to eliminate malignant
cells. But specific antigens of myeloma cells are required [14].
The immunoglobulin (Ig) clones that are produced by
small fractions of residual MM cells are considered ideal
targets for building and specific anti-idiotype vaccines.
However, several clinical studies using anti-idiotype vaccines
targeting the Ig failed to demonstrate benefit in patients with
MM [18].
CTAs have been detected in many cell lines and primary
tumor samples from patients with MM by RT-PCR and im-
munohistochemistry [14]. Despite the little information
available about their importance as clinical prognostic
factors or related to aberrant proliferation of malignant
plasma cells, some studies with diﬀerent tumor cell lines
have shown an association between the expression of CTAs
and a phenotype of resistance to chemotherapy treatments
[42, 43].
There are evidences that CTAs are also expressed in
relapsed MM samples and may be considered important
prognostic markers in newly diagnosed MM patients and in
relapsed cases [44]. On the other hand, the expression of
CTAs in many hematologic malignancies such as leukemia
and B-cell non-Hodgkin’s lymphomas is considered a rare
event [45].
The expression of CTA members of the MAGE family in
tumor cells appears to contribute directly to the malignant
phenotype and poor response to therapy [22, 46, 47]. MAGE
family members are present on the X chromosome and are
described as CTA-X-MAGE. Moreover, all members of this
family present a 200 amino acids common domain, known
as MHD (MAGE Homology Domain), involved in protein-
protein interactions [48, 49].
In our previous study, Andrade et al. [50] showed
that three CTAs (localized on the X chromosome) MAGE-
C1/CT7, MAGE-A3/6, and LAGE-1 were often expressed
in MM suggesting that they could be good candidates for
immunotherapy. According this study, CTA MAGE-C1/CT7
gene was the most frequently expressed CTA in MM and
seems to have prognostic impact in overall survival.
3. MAGE-C1/CT7: New Target for
Immunotherapy in Myeloma
Tumor-specific immunotherapy is a promising strategy for
treating patients with MM, but a T-cell-based therapy
depends on identification of an antigen expressed strictly in
tumor cells. Myeloma is a tumor of B cells and therefore has
the potential to present antigen directly to T cells, although
the ability to present the malignant plasma cells is believed
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Figure 2: Schematic representation of MAGE-C1/CT7 gene: com-
parison of content structure MAGE-C1/CT7 and MAGEA1 genes.
The ORFs (Open Reading Frames) are indicated in green. The black
regions are exons. Repeated region of the MAGE-C1/CT7 gene is
highlighted in exon 4. The gray areas show regions of homology
between the two CTAs (Font: Lucas et al. [53]; modified by de
Carvalho et al. 2011).
to be limited. The antigen presentation of CTA proteins
can thus arise from cross-priming by dendritic cells. Due
to MAGE-C1/CT7 antigen expression in restricted in tumor
cells, it seems to be a promising candidate for immunother-
apy in MM [51].
The CT7 gene is located in the region Xq26-27 (Figure 1)
and was identified by SEREX in the melanoma cell line
SK-MEL-37 and allogeneic serum of melanoma patients
[52]. The CT7 gene is identical to MAGE-C1, identified by
RDA (Representational Diﬀerence Analysis) [53, 54]. Near
the region of MAGE-C1/CT7 are two subfamilies that are
MAGE-B (composed of four genes that are located in the
region Xq21.3) and MAGE-A (with 12 members located
in the region Xq28). MAGE-C1/CT7 represents the first
member of a new subfamily [53].
In evolutionary terms,MAGE-C1/CT7 gene is considered
recent, present in primates (chimpanzee and rhesus) and
humans. MAGE-C1/CT7 protein has a region homologous
to the MAGE family, corresponding to 275 amino acids of
the carboxyl-terminal region. In the amino-terminal region,
a segment composed of tandem repeats presents several
SNPs (Single Nucleotide Polymorphisms) (Figure 2). Themost
common amino acids in this repeated region are serine,
proline, and glutamine, representing 53% of the whole
sequence. MAGE-C1/CT7 is unique compared to MAGE
families’ proteins because the repeated region of this CTA
has a distinct conformation compared to the other MAGE
proteins [52, 53]. Lucas et al. [53] demonstrated that the
repeated region presented in the amino-terminal of MAGE-
C1/CT7 protein ranged from 667 to 1052 amino acids, re-
sulting in the identification of six distinct alleles.
MAGE-C1/CT7 is considered a testis-restricted CTA by
the current classification [6], because it is only expressed in
normal adult testis and several studies have shown that this
CTA is expressed in a wide variety of human tumors [6, 53,
55].
Cho et al. [19] demonstrated that MAGE-C1/CT7 pro-
tein is preferably located in the cytoplasm, but it has also
been found in the cell nucleus. The same authors suggested
that there is physical interaction between MAGE-C1/CT7
and NY-ESO-1 proteins, suggesting that the coordinated
expression of two genes is a common event in many types
of tumors, including MM [19]. Moreover, the expression
of MAGE-C1/CT7 in MM is seen as being restricted to the
malignant plasma cells [14, 34].
Dhodapkar et al. [56] demonstrated that MAGE-
C1/CT7 protein was expressed in most samples from MM,
medullary plasmacytoma, and extramedullary plasmacy-
toma by immunohistochemistry. The same authors also
observed the expression of MAGE-C1/CT7 antigen on the
cell surface of the CAG cell line by flow cytometry and one
case of plasmacytoma by immunohistochemistry, suggesting
the expression of this CTA on the cell surface myeloma.
However this fact should be future investigated because it
was the only study to detect the expression of CTA on the
cell surface [56].
Jungbluth et al. [14] observed that MAGE-C1/CT7 gene
expression is related to disease progression in myeloma due
to its high expression in samples of MM stage III, compared
to individuals with MGUS. Condomines et al. [18] demon-
strated that MAGE-C1/CT7 was more expressed (66%) in
patients with newly diagnosed MM and in those who
survived the treatment. Tinguely et al. [57] showed that
the expression of MAGE-C1/CT7 does not correlated with
survival of malignant plasma cells but observed that patients
with MAGE-C1/CT7 protein located in the cell cytoplasm
had a better prognosis than those patients who showed
protein expression in the nucleus.
Andrade et al. [50] observed high-frequency (77%)
MAGE-C1/CT7 expression in MM patients with advanced
stage and possible unfavorable impact on prognosis related
to expression of this gene. In the same study, the MAGE-
C1/CT7 expression was also observed in patients withMGUS
(33%) and bone marrow of patients with solitary plasmacy-
toma (20%).
Curioni-Fontecedro et al. [58], through an immuno-
genicity study of MAGE-C1/CT7 antigen in vivo, showed
that this CTA was responsible for the high frequency of
specific IgG antibodies in MM patients. Furthermore, they
observed specific immune response against the MAGE-
C1/CT7, demonstrating that antimyeloma immunity can be
generated in patients with this disease.
Atanackovic et al. [59], evaluating the prognostic value
of MAGE-C1/CT7 expression in MM, demonstrated that
patients undergoing allogeneic hematopoietic stem cells
transplant showed early recurrence and worse overall sur-
vival when the malignant plasma cells from bone marrow
expressedMAGE-C1/CT7. The same authors suggest that the
CTAs in general are involved in the progression of myeloma,
further increasing the aggressiveness of the tumor and that
the MAGE-C1/CT7 might be considered as a gatekeeper gene
for other CTAs [59].
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Nuber et al. [55] identified and characterized naturally
occurringMAGE-C1/CT7-specific T lymphocytes in patients
with melanoma expressing this CTA, suggesting a strong
immunogenicity of this antigen and that MAGE-C1/CT7
could be a good candidate for immunotherapy. Lendvai et
al. [60] demonstrated the presence of T lymphocytes specific
for MAGE-C1/CT7 in patients with MM.
Anderson et al. [61] identified immunogenic CD8+ T-
cell epitopes of MAGE-C1/CT7 and demonstrated that these
epitopes are naturally processed and presented by tumor
cells.
Atanackovic et al. [45] throughout transient silencing of
MAGE-C1/CT7 and MAGE-A3 genes suggested that both
CTAs are involved in the survival of myeloma cells, decreas-
ing apoptosis induced by chemotherapy. The same authors
also demonstrated that transient silencing of MAGE-C1/CT7
in MM cell lines aﬀected the MAGE-C2/CT10 expression,
indicating a possible interaction between both genes [45].
Recently, our group (de Carvalho et al.) [24] throughout
stable silencing of MAGE-C1/CT7 by shRNA (Short Hairpin
RNA) in MM cell lines showed that MAGE-C1/CT7 is
involved in survival of malignant plasma cells, protecting
myeloma cells against spontaneous as well as drug-induced
(bortezomib-inhibitor of the 26S ubiquitin/proteasome)
apoptosis. We also suggest that this CTA might play a role in
cell cycle and speculate that silencing MAGE-C1/CT7 might
represent a valuable therapeutic option forMM, in particular
when applied in combination with proteasome inhibitors.
However, the exact function ofMAGE-C1/CT7 protein in the
pathophysiology of MM is not yet understood [24].
4. Concluding Remarks
CTAs are attractive targets for immunotherapy in cancer due
to its limited expression in somatic tissues. These antigens
have been detected in MM patients and might be used for
T-cell immunotherapy. However, we still know little about
the actual role of CTAs in the biology of this incurable
disease. Several studies demonstrate that the MAGE-C1/CT7
is commonly expressed in MM and has important role in
the development and prognosis of the disease, making it a
possible therapeutic target. Nevertheless, further in vitro, in
vivo and clinical studies should be conducted in order to
better understand the participation of MAGE-C1/CT7 and
other CTAs in the MM tumorigenesis and to clarify the
biological pathways in which these proteins act.
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